The effect of high intensity swimming interval training on gene expression of some hippocampal inflammatory markers in rats with Parkinson's disease

Document Type : Original Article

Authors

1 Department of exercise physiology, Shiraz branch, Islamic Azad University, Shiraz, Iran

2 Department of Biology, Shiraz Branch, Islamic Azad University, Shiraz, Iran Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran

Abstract

Background and Objective: Parkinson disease (PD) is a progressive neurodegenerative disease that affects peripheral organs as well as the central nervous system (CNS). The present study was done to examine the effect of high intensity swimming interval training on gene expression of some hippocampal inflammatory markers in rats with PD.
Materials and Methods: In this experimental study, 21 male Wistar rats (aged 8-10 weeks; weight 200 ± 10.2 grams) were divided into three groups including: healthy control, PD and training. PD was induced by injection of 1 mg/kg of reserpine during 5 days. The rats in the training group performed 6 weeks of HIIT including 20 times of 30 seconds of swimming with 30 seconds of rest between each time. Data were analyzed using one-way ANOVA and LSD post hoc test were run using SPSS-22 at the P <0.05.
Results: Data revealed that TNF-α gene expression was reduced after 6 weeks of swimming interval training (p=0.01) compared to the PD group. We observed non-significant decrease in IL-1β after the intervention as compared to the PD group (p=0.6).
Conclusion: According the results of this study, high intensity swimming interval training is effective in reducing the gene expression of some hippocampal inflammatory markers in rats with PD and it is suggested as the effective strategy to improve PD.

Keywords

Main Subjects

References

  1. Pajares M, Rojo AI, Manda G, Boscá L, Cuadrado A.‏ Inflammation in Parkinson’s Disease: Mechanisms and therapeutic implications. Cells. 2020; 9(7): 1687.
  2. Rico D, Vaquerizas JM, Dopazo H, Bosca L. Identification of conserved domains in the promoter regions of nitric oxide synthase 2: Implications for the species-specific transcription and evolutionary differences. BMC Genomics. 2007; 8: 271.
  3. Harms AS, Ferreira SA. Romero-Ramos, M. Periphery and brain, innate and adaptive immunity in Parkinson’s disease. Acta Neuropathology. 2021; 141: 527–545.
  4. Taylor JM, Main BS, Crack PJ. Neuroinflammation and oxidative stress: co- conspirators in the pathology of Parkinson’s disease. Neurochemistry International. 2013; 62(5): 803-819.
  5. Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nature Reviews Immunology. 2022; 22: 657–673.
  6. Collins LM, Toulouse A, Connor TJ, Nolan YM. Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology. 2012; 62(7): 2154-68.
  7. Bargi R, Salmani H, Asgharzadeh Yazdi F, Hosseini M. Inflammation and the brain disorders: A review (Persian). Shefaye Khatam 2017, 5(3): 68-82.
  8. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbatesneurodegeneration and motor symptoms in a model of Parkinson’s disease. Brain. 2018; 131(7): 1880-94.
  9. Mohammdi Z, Fallah mohammadi Z, Aghajani KH, Taghavi A. The pre-treatment effect of voluntary exercise by GDNF on lesion injectioned by 6-hydroxydopamine in brain steam of male rats. Journal of Sport and Exercise Physiology (Persian). 2014; 13:1029-1035.
  10. Abadian F, Fallah mohammadi Z. Neuroprotective effect of voluntary wheel running exercise on GDNF levels of cerebellum in Parkinsonian Rats. Journal of Sport and Exercise Physiology (Persian). 2011; 10:753-759.
  11. Szymura J, Kubica J, Wiecek M, Pera J. The immunomodulatory effects of systematic exercise in older adults and people with Parkinson’s disease. Journal of Clinical Medicine 2020. 9:184.
  12. O’Callaghan A, Harvey M, Houghton D, Gray WK, Weston KL, Oates LL, et al. Comparing the influence of exercise intensity on brain-derived neurotrophic factor serum levels in people with Parkinson’s disease: a pilot study. Aging Clinical and Experimental Research. 2020; 32:1731–1738.
  13. Małczyńska-Sims P, Chalimoniuk M, Sułek A. The effect of endurance training on brain-derived neurotrophic factor and inflammatory markers in healthy people and Parkinson’s disease. Narrative Review Frontiers in Physiology. 2020; 11:578981.
  14. Malczynska-Sims P, Chalimoniuk M, Wronski Z, Marusiak J, Sulek A. High-intensity interval training modulates inflammatory response in Parkinson's disease. Aging Clinical and Experimental Research. 2022; 34(9):2165-2176.
  15. Landers MR, Navalta JW, Murtishaw AS, Kinney JW, Richardson SP. A high intensity exercise boot camp for persons with Parkinson disease: a phase II, pragmatic, randomized clinical trial of feasibility, safety signal of efficacy, and disease mechanisms. Journal of Neurologic Physical Therapy. 2019; 43:12–25.
  16. Colpaert FC. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology. 1987; 26(9): 1431-40.
  17. Khalaj A, Ahmadi R. The effect of treadmill exercise on catalepsy from reserpine-induced Parkinson model in diabetic male rat. Feyz, Journal of Kashan University of Medical Sciences. 2016; 20(5): 397-404.
  18. Alimohamadi Y, Sepandi M. Sample size in animal studies (The number of laboratory animals in a Research study) (Persian). Iranian Journal of Medical Microbiology. 2022; 16(2): 173-176.
  19. Yazdian MR, Khalaj A, Kalhor N. The effect of caloric restriction and treadmill exercise on reserpine-induced catalepsy in a rat model of Parkinson’s disease (Persian). Shefaye Khatam 2018, 6(4): 45-52.
  20. Hubrecht R, Kirkwood J. UFAW Handbook on the care and management of laboratory and other research animals. 8th ed. Wiley-Blackwell Publishing Ltd; 2010. P:460-520.
  21. Shafiee A, Gaeini A, Soleimani M, Nekouei A, Hadidi V. The effect of eight week of high intensity interval training on expression of mir-210 and ephrinA3 mRNA in soleus muscle healthy male rats (Persian). Journal of Arak University of Medical Sciences. 2014;17(3):26-34.
  22. Abbasi M, Kordi M, Daryanoosh F. The effect of eight weeks of high-intensity interval swimming training on the expression of PGC-1α and IL-6 proteins and memory function in brain hippocampus in rats with non-alcoholic steatohepatitis induced by high fat diet. Journal of Applied Health Studies in Sport Physiology. 2023; In press.
  23. Lai TT, Kim YJ, Ma1 H, Kim YE. Evidence of inflammation in Parkinson’s disease and its contribution to synucleinopathy. Journal of Movement Disorders. 2022;15(1):1-14.
  24. Hirsch EC, Standaert DG. Ten unsolved questions about neuroinflammation in Parkinson’s disease. Journal of Movement Disorders. 2021;36:16–24.
  25. Fyfe I. Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease. Nature Reviews Neurology. 2020;16:460.
  26. Fan Z, Pan YT, Zhang ZY, Yang H, Yu SY, Zheng Y, et al. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease. Journal of Neuroinflammation. 2020;17:11.
  27. Usenko TS, Nikolaev MA, Miliukhina IV, Bezrukova AI, Senkevich KA, Gomzyakova NA, et al. Plasma cytokine profile in synucleinophaties with dementia. Journal of Clinical Neuroscience. 2020;78:323–326.
  28. Amin J, Holmes C, Dorey RB, Tommasino E, Casal YR, Williams DM, et al. Neuroinflammation in dementia with Lewy bodies: a human postmortem study. Translational Psychiatry. 2020;10:267.
  29. Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, et al. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease. Journal of Neuroinflammation. 2017;14:164.
  30. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-α. Nature. 2006;440(7087):1054–9.
  31. Islam MT. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurology Research. 2017;39(1):73–82.
  32. El Kattan MM, Rashed LA, Shazly SR, Ismail RS. Relation of serum level of tumor necrosis factor alpha to cognitive functions in patients with Parkinson’s disease. Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2022; 58:25-32.
  33. Leal MC, Casabona JC, Puntel M, Pitossi FJ. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease? Frontiers in Cellular Neuroscience. 2013; 7:1-10.
  34. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nature Neuroscience. 2014;17:131–143.
  35. Zhou X, Spittau B, Krieglstein K. TGFβ signalling plays an important role in IL4-induced alternative activation of microglia. Journal of Neuroinflammation. 2012;9:210.
  36. Chen X, Liu Z, Cao BB, Qiu YH, Peng YP. TGF-β1 Neuroprotection via inhibition of microglial activation in a rat model of Parkinson’s disease. Journal of Neuroimmune Pharmacology. 2017;12:433–
Daneshvar Medicine
Volume 31, Issue 6 - Serial Number 169
March and April 2024
Pages 37-45

Files

Share

How to cite

Statistics